|
HHS Biannual Dual Use Research of Concern (DURC) Inventory
|
Resource Development
|
CDC, FDA, OS
|
OD/OSP, CC, FIC, NCATS, NCCAM, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
Development of the HHS biannual Dual Use Research of Concern (DURC) inventory reports, as required by the USG Policy for Oversight of Dual Use Research of Concern.
|
|
HHS Biomedical Advanced Research and Development Authority (BARDA) Radiological/Nuclear Integrated Program Team
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
This Interagency Working Group, established under the Biomedical Advanced Research and Development Authority (BARDA), determines overall radiation countermeasures strategy and priorities. The National Institute of Allergy and Infectious Diseases (NIAID) provides subject matter expertise, advice and guidance on medical countermeasure development, requirements, and preparedness/response.
|
|
HHS Biovigilance Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC, NHLBI
|
This committee develops systems for reporting adverse events resulting from blood transfusion or donation.
|
|
HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, OS
|
NHLBI, CC
|
The mission of the HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is to serve as the Department''s internal executive leadership coordination mechanism across all the staff and operating divisions involved in blood, organ, and tissue safety and blood product availability. The BOTSEC is chaired by the Assistant Secretary for Health and voting members are the senior-most heads of the relevant Staff divisions and Operating divisions of HHS (e.g., the Director of CDC and NIH, Administrator of CMS, and Commissioner of FDA). The BOTSEC is an internal council chartered to consider significant issues and make decisions that require cross-Agency input, including resources. In important aspect of the BOTSEC is the formation of HHS-wide (i.e., multi-Agency) working groups to explore significant public health items such as re-examining the lifetime blood donor deferral policy for MSM, and the creation of hemovigilance systems to collect and analyze data on adverse events that occur during the blood donation and utilization processes. The internal committee is also responsible for looking at providing timely recommendations on emerging issues that are taking place. It also provides decisional elements on proposed policies, public health threats, and issues related to blood, organ, and tissue safety and availability. The staff of the Public Health Service (PHS) operating divisions involved in blood, organ and tissues safety (BOTS) meet monthly by a teleconference call.
|
|
HHS Climate Adaptation Strategies
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIEHS
|
NIEHS has been partnering with the Assistant Secretary for Administration (ASA) and more recently the Assistant Secretary for Preparedness and Response (ASPR) and other operating and staff divisions of HHS to respond to White House directives on climate change adaptation at the agency level. This includes production of the HHS Climate Adaptation Plan and the coordination and production of deliverables under the President''s Climate Action Plan.
|
|
HHS Diagnostics Integrated Program Team (DxIPT)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
The DxIPT was established by the USG Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Executive Committee. The DxIPT will advise leadership on investments in human health diagnostics, medical countermeasures to improve the response to chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. Members include Federal employees or contractors to the Federal Government with diverse expertise in diagnostics. In 2012, DxIPT was charged with two tasks: 1) to reevaluate the feasibility of anthrax diagnostics for asymptomatic infections and 2) to develop Quantitative Technological Readiness Levels (Q-TRLs) for diagnostics to represent milestones and activities for the product development lifecycle from discovery through post-approval.
|
|
HHS Dietary Guidance Review Committee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, FDA, HRSA, IHS, OS
|
NIDDK
|
This committee reviews draft nutrition materials developed by all federal agencies and fulfills the legislative mandate (1990 NNMRRA) to ensure that Federal dietary guidance is consistent with the Dietary Guidelines for Americans and is scientifically accurate.
|
|
HHS Disability and Health Workgroup for Healthy People 2020
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD
|
The purpose of this workgroup is to discuss the measurement of health and the targets for persons with disabilities.
|
|
HHS Environmental Justice Team
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIEHS, NIMHD, NLM
|
Collaboration of HHS Operational Divisions under the leadership of OASH. The group works together to help advance HHS progress toward the HHS Environmental Justice (EJ) Strategy. It shares updates about EJ issues and concerns. The group also plans EJ-focused meetings and sessions for national conferences.
|
|
HHS Global Health Collaboration
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, HRSA, SAMHSA
|
OD/DPCPSI/OAR
|
Federal working group established to communicate and share information related to global health activities within HHS.
|